Cyclocreatine and
its water-soluble derivative, cyclocreatine phosphate
(CCrP), are potent cardioprotective drugs. Based on recent animal
studies, CCrP, FDA-awarded Orphan Drug Designation, has a promising
role in increasing the success rate of patients undergoing heart transplantation
surgery by preserving donor hearts during transportation and improving
the recovery of transplanted hearts in recipient patients. In addition,
CCrP is under investigation as a promising treatment for creatine
transporter deficiency, an X-linked inborn error resulting in a poor
quality of life for both the patients and the caregiver. A newly designed
molecularly imprinted polymer (MIP) material was fabricated by the
anodic electropolymerization of o-phenylenediamine
on screen-printed carbon electrodes and was successfully applied as
an impedimetric sensor for CCrP determination to dramatically reduce
the analysis time during both the clinical trial phases and drug development
process. To enhance the overall performance of the proposed sensor,
studies were performed to optimize the electropolymerization conditions,
incubation time, and pH of the background electrolyte. Scanning electron
microscopy, electrochemical impedance spectroscopy, and cyclic voltammetry
were used to characterize the behavior of the developed ultrathin
MIP membrane. The CCrP-imprinted polymer has a high recognition affinity
for the template molecule because of the formation of 3D complementary
cavities within the polymer. The developed MIP impedimetric sensor
had good linearity, repeatability, reproducibility, and stability
within the linear concentration range of 1 × 10–9 to 1 × 10–7 mol/L, with a low limit of detection
down to 2.47 × 10–10 mol/L. To verify the applicability
of the proposed sensor, it was used to quantify CCrP in spiked plasma
samples.